Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Agenus Inc (NASDAQ:AGEN)

4.10
Delayed Data
As of Dec 02
 +0.15 / +3.80%
Today’s Change
2.61
Today|||52-Week Range
7.49
-9.69%
Year-to-Date
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
Dec 01 / Zacks.com - Paid Partner Content
3 Red Flags on Agenus Inc's Balance Sheet
Nov 23 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close3.95
Today’s open3.95
Day’s range3.93 - 4.21
Volume1,118,125
Average volume (3 months)1,326,631
Market cap$356.7M
Dividend yield--
Data as of 3:59pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)-59.15%
Earnings growth (this year)-28.50%
Earnings growth (next 5 years)+1.00%
Revenue growth (last year)+255.67%
P/E ratioNM
Price/Sales14.31
Price/Book5.01

Competitors

 Today’s
change
Today’s
% change
VYGRVoyager Therapeutics...+0.50+3.84%
NDRMNeuroderm Ltd0.000.00%
BTXBioTime Inc-0.06-1.85%
BOLDAudentes Therapeutic...+0.41+2.53%
Data as of 4:00pm ET, 12/02/2016

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)-$0.30
Annual revenue (last year)$24.8M
Annual profit (last year)-$87.9M
Net profit margin-354.12%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Garo H. Armen
Chief Financial &
Accounting Officer
Christine M. Klaskin
Corporate headquarters
Lexington, Massachusetts

Forecasts


Search for Jobs